肾小球疾病的管理与治疗(第一部分):KDIGO争议会议结论
专家组共识认为多数指南推荐(尤其治疗相关)需由指南更新工作组重新审视。本报告涵盖肾小球疾病一般管理、IgA肾病和膜性肾病。
要点
- 2012年KDIGO指南中多数推荐(尤其治疗相关)需更新。
- 会议聚焦肾小球疾病命名、发病机制、诊断与治疗新进展。
- 本报告涉及一般管理、IgA肾病和膜性肾病。
核心结论
- 专家组共识认为2012年KDIGO指南中多数推荐(尤其治疗相关)需由指南更新工作组重新审视。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.
引用
- Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019. PMID: 30665568. doi:10.1016/j.kint.2018.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。